HRAS and PI3K-AKT pathway mutations identified by massively parallel sequencing were found to be clonal in the vast majority of cases and truncal in the three cases subjected to sequencing analysis of different components (i.e., primary adenomyoepithelioma, carcinoma and/or metastatic lesions), consistent with the notion that these mutations likely constitute founder genetic events in the development of adenomyoepitheliomas. The gene discussed is PIK3CA; the disease is carcinoma.